Fibro­sis is a nor­mal phys­i­o­log­i­cal response to injury. It acts to deposit con­nec­tive tis­sues in the injured area, there­by pro­mot­ing heal­ing and rein­forc­ing tis­sue remod­el­ing. How­ev­er, this nor­mal phys­i­o­log­i­cal response can some­times over­shoot and that’s when fibro­sis can be dan­ger­ous. Such cas­es are what we refer to as fibro­­sis-relat­ed dis­eases. In a fibro­­sis-relat­ed dis­ease, what hap­pens is, the reg­u­la­to­ry path­way for fibro­sis is dis­turbed by pathogens. Cells that take part in the phys­i­o­log­i­cal response start act­ing abnor­mal­ly, caus­ing excess depo­si­tion of con­nec­tive tis­sues in the injured area. This excess depo­si­tion can inter­fere with the nor­mal func­tion and archi­tec­ture of the under­ly­ing tis­sue or organ. If not stopped, it can com­plete­ly over­whelm the tis­sue (or organ) and cause tis­sue death. Over the years, sev­er­al com­pounds have been test­ed for treat­ing fibro­­sis-relat­ed dis­eases. But no com­pound has received as much atten­tion as halofug­i­none — a syn­thet­ic halo­genat­ed vari­ant of febrifug­ine.

Halofug­i­none – Can It Treat Fibro­­sis-Relat­ed Diseases ?

The ear­ly signs are pos­i­tive : Halofug­i­none has been found to inhib­it the expres­sion of col­la­gen type 1 pro­tein (a key medi­a­tor of fibro­­sis-relat­ed dis­eases) in cul­tures of murine, avian and human skin fibrob­lasts. All fibro­­sis-relat­ed dis­eases are char­ac­ter­ized by high expres­sion of col­la­gen type 1 pro­teins. If the expres­sion of this pro­tein can be atten­u­at­ed in the pro­tag­o­nist cells orches­trat­ing the fibro­sis response, these dis­eases can be con­trolled. And so, halofug­i­none was put to test to see how effec­tive­ly it could inhib­it the expres­sion of col­lage type 1 pro­teins in abnor­­mal­­ly-respond­ing cells. Cell cul­tures were devel­oped from bio­log­i­cal sam­ples tak­en from patients suf­fer­ing from fibro­­sis-relat­ed dis­eases. Halofug­i­none was intro­duced inside these cul­tures. What was the result ? Sci­en­tists found a dras­tic decrease in the expres­sion of col­lage type 1 pro­teins in the stud­ied cells. Halofug­i­none has also been test­ed in ani­mal mod­els to great suc­cess, pre­vent­ing col­la­gen syn­the­sis in mice and rats afflict­ed with cGvHD and pul­monary fibro­sis. How­ev­er, what has real­ly piqued everyone’s inter­est in the com­pound is its abil­i­ty to elic­it the res­o­lu­tion of estab­lished fibro­sis ; this prop­er­ty makes the com­pound unique. Yes, halofug­i­none has been found to avert fibro­­sis-relat­ed con­di­tions in a research con­duct­ed on rats. What we are poten­tial­ly look­ing at is a solu­tion that may not only be able to stop exces­sive fibro­sis but may also be able to treat it — com­plete­ly ! A BONUS read :Ana­lyz­ing the Ver­sa­til­i­ty of Halofuginone